NEW YORK — CosmosID has partnered with Spanish microbiome consulting firm Sandwalk BioVentures to launch a service that will provide generally recognized as safe, or GRAS, regulatory genomic reporting for the US probiotics market, the companies said on Thursday.
According to the companies, the service will combine CosmosID's microbial genomics infrastructure with Sandwalk's regulatory know-how to offer genomic sequencing and analysis to companies developing next-generation functional bacterial strains. The so-called Genomic Sequencing and Reporting Bundle will also provide regulatory-compliant safety reports that can be included in GRAS dossiers that are legally required for new probiotics entering the US market.
Additional terms of the deal were not disclosed.
"CosmosID has been supporting probiotic and live biotherapeutic companies with bacterial isolate sequencing and analysis for a number of years," CosmosID CEO Manoj Dadlani said in a statement. "Now, through our partnership with Sandwalk, we have the ability to now offer regulatory reporting to our customers, as well. Through this complete solution, we have all of the necessary lab, bioinformatic, and consulting expertise to help bring novel microbial products to the market."
Originally focused on developing bioinformatics tools for microbial analysis, Rockville, Maryland-based CosmosID began offering full metagenomic and microbiome next-generation sequencing services about two years ago, with the goal of eventually moving into clinical testing and diagnostics.